

MAY 28 2002 16:19 FR BROBECK

TO 917038729307

# FACSIMILE TRANSMISSION

Transmission problems: 858-720-2946

May 28, 2002

FAX RECEIVED

MAY 29 2002

GROUP 1600

Brobeck

ATTORNEYS AT LAW

Brobeck, Phleger & Harrison LLP

12750 High Bluff

Suite 300

San Diego, California 92130-2081

PHONE 858.720.2500

FAX 858.720.3700

www.brobeck.com

ORIGINAL

PAGES TO FOLLOW COVER	7	USER ID	100454	CMID NUMBER	030639.0034.CPA2
-----------------------	---	---------	--------	-------------	------------------

## TO

RECIPIENT	COMPANY	TELEPHONE	FAX
Examiner Nolan	U.S. Patent & Trademark Office	703-305-1987	703-872-9307

## FROM

SENDER	EMAIL	TELEPHONE	FAX
Lisa McGechan	<a href="mailto:lmcgechan@brobeck.com">lmcgechan@brobeck.com</a>	(858) 720-2584	(858) 720-3700

## MESSAGE

Re: Application Serial No. 09/280,020

### PRIVILEGED AND CONFIDENTIAL

All information transmitted hereby is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and mail the original message to us at the above address.

SDILB1LM03444070.01

Received from < > at 5/28/02 7:16:07 PM [Eastern Daylight Time]

E

PATENT  
030639.0034.CPA2IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John Dupre

Serial No.: 09/280,020

Filed: March 29, 1999

Title: **TREATMENT OF DIABETES**

Group Art Unit: 1644

Examiner: Nolan, P.

**FAX RECEIVED**  
**MAY 29 2002**  
**GROUP 1600**Box AF  
Commissioner for Patents  
Washington, D.C. 20231RESPONSE AFTER FINAL

Dear Sir:

O.k. to  
ENTER  
P.N.  
6/25/02

This communication is responsive to the Final Office Action mailed February 26, 2002, in the above-identified patent application. As this Response is being filed within the shortened three-month period for response, it is believed that no additional fee is due therefor. If, however, any fee should become due, or credit become payable, during the pendency of these proceedings, the Examiner is authorized to charge or credit the same to deposit account number 50-1273.

Applicant thanks the Examiner for granting a telephonic interview for discussion of the Final Office Action in the present application. The telephonic interview occurred on May 21, 2002, between Examiner Nolan and Applicant's Representatives, Bradford Duft and Lisa McGeehan. Agreement was reached to withdraw all outstanding rejections upon filing a terminal disclaimer which would render the rejection for alleged double patenting moot. The substance of the interview is incorporated throughout this response.

AMENDMENT

Please amend the application as follows:

In the ClaimsE1 2236. (Once Amended) The method of claim <sup>21</sup>36 further comprising administering an insulin.CERTIFICATE OF TRANSMISSION  
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being transmitted, via facsimile, to the United States Patent and Trademark Office on the date indicated below.

Lisa M. McGeehan  
Lisa M. McGeehan

Date

May 28, 2002

C:\N:\Portbl\SDILIB\NLM03\443597\_1.DOC